Clinical and biochemical characteristics.

CN: Myeloma Cast Nephropathy;LCDD: Light Chain Deposition Disease; MM: Multiple Myeloma; AKI: acute kidney injury. Values are mean ±SD or median (range)* 1 subject had two distinct episodes of AKIOne patient received bortezomid- and Revlimid-based regimen. Another patient with two episodes of AKI received Bortezomib and Revlimid respectively for the first and second episode.Clinical and biochemical characteristics.

骨髓瘤管型肾病（Myeloma Cast Nephropathy）；轻链沉积病（Light Chain Deposition Disease, LCDD）；多发性骨髓瘤（Multiple Myeloma, MM）；急性肾损伤（acute kidney injury, AKI）。数据以均值±标准差或中位数（范围）呈现。* 1名受试者出现2次独立的急性肾损伤发作。1例患者接受了以硼替佐米（bortezomid）和来那度胺（Revlimid）为基础的治疗方案。另有1例存在2次急性肾损伤发作的患者，其首次与第二次发作分别接受了硼替佐米与来那度胺治疗。临床及生化特征。